OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course.

Chief Financial Officer Andrew Dickinson told investors at the Barclays conference that the company is entering what he ...

Gilead has handed back a next-gen hepatitis B antiviral to Assembly Biosciences, while the two companies continue to partner ...

As it ramps up its rollout of the first twice-yearly HIV pre-exposure prophylaxis (PrEP) medicine, Gilead Sciences is tapping into a beloved early-aughts track to familiarize consumers with Yeztugo.

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro MedicinesNew partnership structure ...

Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.

Gilead Sciences Inc. said it would acquire Ouro Medicines, a closely held company testing novel antibody drugs against autoimmune diseases, for as much as $2.18 billion.